The results of a second randomised, double-blind placebo-controlled phase 2 study (PRM-151-202) of IPF patients receiving recombinant human pentraxin-2 in intravenous infusions in comparison with placebo showed a significantly slower decline in pulmonary function and improved physical capacity in the PRM-151 group. Here, APCS is linked to idiopathic pulmonary fibrosis.